Early Effects of Oral Pulmonary Vasodilators in an Elderly Patient with Critical Thromboembolic Pulmonary Hypertension: A Case Report

Hirotake Okazaki¹, Noritake Hata¹, Akihiro Shirakabe¹, Masafumi Tsurumi¹, Takuro Shinada¹ and Wataru Shimizu²

¹Division of Intensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital
²Department of Cardiovascular Medicine, Nippon Medical School

A 70-year-old woman who had been treated for bipolar disorder and dementia was admitted to the intensive care unit of a university hospital with severe dyspnea; pulmonary arterial hypertension was diagnosed after cardiac catheterization was performed. Computed tomography pulmonary angiography showed typical signs of chronic thrombosis in the proximal pulmonary artery without an adequate amount of fresh thrombi, which appeared to be the cause of the elevation in pulmonary artery pressure, and resulted in severe hypoxemia. Therefore, the pulmonary arterial hypertension was classified as belonging to the chronic thromboembolic pulmonary hypertension subgroup. Although the patient’s respiratory condition was classified as World Health Organization class IV, she was treated with the combination of oral ambrisentan and tadalafil, rather than intravenous epoprostenol, which she was unable to tolerate. Consequently, both her symptom and hemodynamic status showed rapid improvement with only oral pulmonary vasodilators. This case demonstrates the efficacy of oral treatment alone in elderly patients with severe chronic thromboembolic pulmonary hypertension.

(J Nippon Med Sch 2015; 82: 206–210)

Key words: pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, specific pulmonary vasodilators, ambrisentan, tadalafil

Introduction

For pulmonary arterial hypertension (PAH) in patients with severe respiratory disease (World Health Organization [WHO] class IV) the optimal treatment is recommended to not be based on oral agents alone but also to include intravenous epoprostenol. This strategy has gained acceptance for all subgroups of PAH, despite its efficacy varying according to the etiology. However, epoprostenol cannot always be administered intravenously because some patients cannot tolerate the drug. Nevertheless, few studies have examined the use of oral specific pulmonary vasodilators in critically ill patients with PAH.

Case Presentation

A 70-year-old woman who had been previously treated for bipolar disorder and dementia was admitted to the intensive care unit of our hospital with severe dyspnea. Physical examination at admission revealed systemic cyanosis, jugular venous distention, and hypotension (90/40 mm Hg). Arterial blood gas analysis (oxygen inhalation at 9 L/min via a face mask) disclosed hypoxia, hypocapnia reflecting tachypnea, and an extremely high alveolar-arterial oxygen tension difference ([A-a DO₂] pH: 7.411; PO₂: 67.2 mmHg; PCO₂: 34.0 mm Hg; HCO₃⁻: 26.5 mmol/L; and calculated A-a DO₂: 318.1 mmHg). Electrocardiography showed sinus rhythm without right ventricular hypertrophy, and radiography of the chest revealed cardiomegaly without pulmonary congestion. In addition, transthoracic echocardiography (TTE) revealed a significantly dilated right atrium and ventricle with a moderate amount of pericardial effusion, although no left ventricular dysfunction was observed (Fig. 1A). The tricuspid regurgitation pressure gradient (TRPG) was greater than...
might have had a history of pulmonary embolization. Therefore, we considered that the patient thrombus in the right peripheral pulmonary artery noted did not appear to be caused by the small, fresh mission. The multiple defects on lung perfusion scintigra-
sult contradicted the findings of CTPA obtained on ad-
thesis of chronic pulmonary thromboembolism (CTEPH) (Fig. 1B). Although a small, fresh thrombus in the right peripheral pulmonary artery was found on CTPA on admission, it was not considered to be the cause of the patient’s severe PAH and hypoxemia.

Cardiac catheterization performed on the third hospital day indicated severe pulmonary hypertension (systolic pulmonary arterial pressure: 82 mmHg; mean pulmonary arterial pressure: 45 mmHg) without elevation of the pulmonary capillary wedge pressure (14 mmHg), and PAH was subsequently diagnosed.

Lung perfusion scintigraphy performed after the patient showed clinical improvement demonstrated bilateral multiple segmental and sphenic defects (Fig. 3). This result contradicted the findings of CTPA obtained on admission. The multiple defects on lung perfusion scintigraphy did not appear to be caused by the small, fresh thrombus in the right peripheral pulmonary artery noted on CTPA. Therefore, we considered that the patient might have had a history of pulmonary embolization.

On the basis of these findings, chronic pulmonary thromboembolic pulmonary hypertension (CTEPH) was diagnosed. The acute-phase clinical course in the intensive care unit is shown in Figure 4. The patient received mechanical ventilatory support with an endotracheal tube because of her poor respiratory condition. Ambis-
entan (5 mg/day) was administered orally to decrease the pulmonary artery pressure in addition to anticoagulation therapy and intravenously infused catecholamines. Following the additional administration of tadalafil (20 mg/day), the blood pressure increased (from 76/40 mmHg to 112/52 mmHg), and the heart rate and respiratory rate stabilized. On the fifth hospital day, the dose of ambris-
entan was increased to 7.5 mg, and urine output in-
creased. Treatment with ambrisentan and tadalafil also decreased the TRPG on TTE to 10 mmHg over 1 week, and the left ventricle was no longer D-shaped on cross-sectional images (Fig. 1C).

Furthermore, the oral combination therapy resulted in hemodynamic stability, and the intravenous catechola-
mines were discontinued on the eighth hospital day. Follow-up cardiac catheterization on the eighth hospital day revealed a marked decrease in systolic pulmonary arterial pressure (from 82 to 50 mmHg) and an increase in the cardiac index (from 2.83 to 3.53 L/min/m²). In addition, the pulmonary vascular resistance significantly decreased to 280 dyn·sec/cm², and the patient’s respiratory condition gradually improved as the pulmonary arterial pressure decreased. No adverse events related to
Computed tomography pulmonary angiography (CTPA) on admission showed enlarged bilateral main pulmonary arteries, and only small, fresh thrombus in the right peripheral pulmonary (A). There were linear filling defects in the right main pulmonary artery which were thought to indicate a residual previous thrombus and regarded as typical sign of chronic thromboembolic pulmonary hypertension (B). These defects were still present several months later after the patients respiratory function had improved.

Lung perfusion scintigraphy after the patient’s clinical improvement demonstrated bilateral multiple segmental and sphen defects characteristic of chronic thromboembolic hypertension. The findings differed significantly from those of CTPA on admission.

Discussion
CTEPH is included in Group IV in the cause-specific Dana Point Classification proposed during the 4th World Symposium on Pulmonary Hypertension1. Because CTPH has a poor prognosis, it should be diagnosed as soon as...
Oral Combination Therapy for Severe CTEPH

In the present case, the patient was first found to have PAH. However, the pathophysiology on admission might have involved acute or chronic PTE, such that anticoagulation therapy could have improved the respiratory condition. However, we believed that the illness was caused primarily by chronic, not acute, PTE for the following 4 reasons. First, CTPA on admission demonstrated typical findings strongly suggesting CTEPH, such as linear filling defects, called “bands,” thought to be indicative of residual thrombi. Second, the fresh thrombus in the right peripheral pulmonary artery detected on admission did not seem to explain the severe PAH and hypoxemia. Third, although the fresh thrombus found on CTPA was present in only the right peripheral pulmonary artery, lung perfusion scintigraphy demonstrated multiple defects in the bilaterally diffused lung fields. These conflicting findings prevented acute PTE from being diagnosed. In fact, previous reports have shown that CTPA is much less sensitive for chronic PTE than is lung perfusion scanning. Finally, the typical signs of CTEPH observed with CTPA on admission remained several months later, after the patient’s condition had improved.

Unlike patients with other PAH disorders, patients with severe CTEPH can receive curative surgical therapy, if feasible; however, the present patient was thought to be a poor surgical candidate. According to several guidelines and reviews, medical treatment for severe CTEPH (WHO functional class IV) is similar to that for other PAH disorders, and epoprostenol should be continuously and intravenously administered. In the present case, the patient’s condition was critical (WHO functional class IV), with TTE on admission showing severe right heart loading and pericardial effusion. Despite the patient’s critical respiratory condition, we were reluctant to administer epoprostenol because of her severe dementia and bipolar disorder.

Recently, oral treatment for CTEPH has improved with the introduction of specific oral vasodilators, including endothelin receptor antagonists (ERAs) and phosphodiesterase 5 (PDE5) inhibitors. However, most previous studies of these agents for CTEPH limited their target populations to outpatients in noncritical condition and evaluated the treatment efficacy at least several months after administration. Therefore, the acute-phase (within several days or weeks) response to these oral agents is unclear. Furthermore, the efficacy of combination therapy with ERAs and PDE5 inhibitors for CTEPH remains unknown.

We chose ambrisentan among the ERAs because it is less likely than bosentan to interact with other drugs. Ghofrani et al. have reported that the area under the
curve for PDE5 inhibitors decreases by 42% to 63% when these agents are used in combination with bosentan. We selected tadalafil from among the PDE5 inhibitors because of its safety and rapid onset of action. Tadalafil was first administered at half the typical dosage (20 mg/day) because of the patient’s acute kidney injury due to circulatory failure and diuresis; it was then administered at the standard dosage (40 mg/day) following her recovery from acute kidney injury.

In summary, we have successfully treated a case of severe CTEPH in an elderly patient using only oral PAH agents (ambrisentan and tadalafil). The accumulation of additional cases is required to determine the optimal method of treating severe CTEPH with oral agents alone.

Conflict of Interest: The authors declare no conflict of interest.

References

(Received, September 10, 2014)
(Accepted, January 8, 2015)